Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OKI-005 + Tunlametinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OKI-005 | HDAC Inhibitor 45 | OKI-005 inhibits histone-deacetylase, which may lead to enhanced tumor immunogenicity and sensitize tumor cells to immunotherapy (PMID: 31235619). | ||
Tunlametinib | HL-085|HL085|HL 085 | MEK inhibitor (Pan) 26 | Tunlametinib (HL-085) is a MEK inhibitor that may inhibit proliferation of tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 4753). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|